(NASDAQ: BRTX) Biorestorative Therapies's forecast annual revenue growth rate of 511.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 24.07%.
Biorestorative Therapies's revenue in 2026 is $383,400.On average, 4 Wall Street analysts forecast BRTX's revenue for 2026 to be $17,202,157, with the lowest BRTX revenue forecast at $11,308,332, and the highest BRTX revenue forecast at $23,300,135. On average, 4 Wall Street analysts forecast BRTX's revenue for 2027 to be $433,888,461, with the lowest BRTX revenue forecast at $27,187,929, and the highest BRTX revenue forecast at $864,182,045.
In 2028, BRTX is forecast to generate $763,481,079 in revenue, with the lowest revenue forecast at $32,620,189 and the highest revenue forecast at $1,536,921,302.